Abstract:Objective: This study was aimed at exploring the accuracy of population pharmacokinetic method in evaluating the bioequivalence of pidotimod with sparse data profiles and whether this method is suitable for bioequivalence evaluation in special populations such as children with fewer samplings. Methods: In this single-dose, two-period crossover study, 20 healthy male Chinese volunteers were randomized 1 : 1 to receive either the test or reference formulation, with a 1-week washout before receiving the alternative formulation. Noncompartmental and population compartmental pharmacokinetic analyses were conducted. Simulated data were analyzed to graphically evaluate the model and the pharmacokinetic characteristics of the two pidotimod formulations. Various sparse sampling scenarios were generated from the real bioequivalence clinical trial data and evaluated by population pharmacokinetic method. Results: The 90% confidence intervals (CIs) for AUC(0-12h), AUC(0-infinity), and C-max were 97.3 - 118.7%, 96.9 - 118.7%, and 95.1 - 109.8%, respectively, within the 80 - 125% range for bioequivalence using noncompartmental analysis. The population compartmental pharmacokinetics of pidotimod were described using a one-compartment model with first-order absorption and lag time. In the comparison of estimations in different dataset, the estimation of random three-and fixed four-point sampling strategies can provide results similar to those obtained through rich sampling. The nonlinear mixed-effects model requires fewer data points. Moreover, compared with the noncompartmental analysis method, the pharmacokinetic parameters can be more accurately estimated using nonlinear mixed-effects model. Conclusions: The population pharmacokinetic modeling method was used to assess the bioequivalence of two pidotimod formulations with relatively few sampling points and further validated the bioequivalence of the two formulations. This method may provide useful information for regulating bioequivalence evaluation in special populations.

Random Sparse Sampling Strategy Using Stochastic Simulation and Estimation for a Population Pharmacokinetic Study

[Modeling and Simulation Activities to Design Sampling Scheme for Population Pharmacokinetic Study on Amlodipine].

A simulation study of sampling time point designing for therapeutic drug monitoring based on a population pharmacokinetic model

494 POWER ESTIMATION USING MODELING AND SIMULATION ACTIVITIES TO DESIGN SAMPLING SCHEME FOR PK/PD STUDY ON AMLODIPINE TREATED AS AN ANTIHYPERTENSIVE DRUG IN PATIENTS WITH RENAL IMPAIRMENT AND HYPERTENSION

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Limited Sampling Strategy Models for Estimating AUC for Amlodipine in Chinese Healthy Volunteers

Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling

Reinforcement Learning Based Model Selection and Parameter Estimation for Pharmacokinetic Analysis in Drug Selection.

Advantage Of A Population Pharmacokinetic Method For Evaluating The Bioequivalence And Accuracy Of Parameter Estimation Of Pidotimod

Parameter Estimation of Population Pharmacokinetic Models with Stochastic Differential Equations: Implementation of an Estimation Algorithm

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Estimating Treatment Effects Using Costly Simulation Samples from a Population-Scale Model of Opioid Use Disorder

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

A simulation study on model‐informed precision dosing of amikacin for achieving target area under the concentration–time curve

Efficient and flexible simulation-based sample size determination for clinical trials with multiple design parameters

Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?

Modeling Pharmacokinetics in Individual Patients Using Therapeutic Drug Monitoring and Artificial Population Quasi-Models: A Study with Piperacillin

A Quick and Accurate Method for the Estimation of Covariate Effects Based on Empirical Bayes Estimates in Mixed-Effects Modeling: Correction of Bias Due to Shrinkage.

Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments

Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors

Limited sampling approach for model‐informed precision dosing of daptomycin to rapidly achieving the target area under the concentration‐time curve: A simulation study